Brokerages Expect Gamida Cell Ltd. (NASDAQ:GMDA) Will Post Earnings of -$0.38 Per Share

Wall Street brokerages expect that Gamida Cell Ltd. (NASDAQ:GMDA) will announce earnings of ($0.38) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Gamida Cell’s earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.42). Gamida Cell reported earnings per share of ($0.37) during the same quarter last year, which indicates a negative year-over-year growth rate of 2.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, August 10th.

According to Zacks, analysts expect that Gamida Cell will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.43). For the next financial year, analysts expect that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.97) to ($0.58). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Gamida Cell.

Gamida Cell (NASDAQ:GMDA) last posted its quarterly earnings results on Monday, May 10th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.09.

A number of brokerages have commented on GMDA. Piper Sandler decreased their target price on Gamida Cell from $25.00 to $23.00 in a research note on Tuesday, March 9th. Zacks Investment Research upgraded Gamida Cell from a “sell” rating to a “hold” rating in a research note on Friday, May 14th. Finally, Needham & Company LLC decreased their target price on Gamida Cell from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, March 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $20.25.

Shares of GMDA stock opened at $6.58 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 8.97 and a current ratio of 8.97. The company has a 50 day moving average of $7.03. Gamida Cell has a 52 week low of $3.86 and a 52 week high of $15.00. The firm has a market capitalization of $159.37 million, a P/E ratio of -3.89 and a beta of 1.93.

A number of large investors have recently made changes to their positions in the stock. Federated Hermes Inc. raised its holdings in Gamida Cell by 184.2% during the fourth quarter. Federated Hermes Inc. now owns 5,052,523 shares of the company’s stock worth $42,391,000 after purchasing an additional 3,274,746 shares in the last quarter. Rock Springs Capital Management LP grew its position in Gamida Cell by 0.3% in the first quarter. Rock Springs Capital Management LP now owns 2,100,300 shares of the company’s stock worth $16,991,000 after buying an additional 6,300 shares during the last quarter. Baker BROS. Advisors LP grew its position in Gamida Cell by 144.5% in the fourth quarter. Baker BROS. Advisors LP now owns 1,548,314 shares of the company’s stock worth $12,990,000 after buying an additional 914,990 shares during the last quarter. JPMorgan Chase & Co. grew its position in Gamida Cell by 4,367,658.3% in the first quarter. JPMorgan Chase & Co. now owns 1,048,262 shares of the company’s stock worth $8,480,000 after buying an additional 1,048,238 shares during the last quarter. Finally, ARK Investment Management LLC grew its position in Gamida Cell by 108.2% in the first quarter. ARK Investment Management LLC now owns 670,324 shares of the company’s stock worth $5,423,000 after buying an additional 348,298 shares during the last quarter.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Read More: Current Ratio

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.